menu
    • menu
    [{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Evotec","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"GERMANY","productType":"Cell and Gene therapy","year":"2020","type":"Collaboration","leadProduct":"Induced pluripotent stem cells","moa":"","graph1":"Neurology","graph2":"Undisclosed","graph3":"Bristol Myers Squibb","amount2":0.01,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0.01,"dosageForm":"","sponsorNew":"Bristol Myers Squibb \/ Bristol-Myers Squibb","highestDevelopmentStatusID":"1","companyTruncated":"Bristol Myers Squibb \/ Bristol-Myers Squibb"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Nektar Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Collaboration","leadProduct":"Axitinib","moa":"IL-2 beta receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Bristol Myers Squibb \/ Bristol-Myers Squibb","highestDevelopmentStatusID":"7","companyTruncated":"Bristol Myers Squibb \/ Bristol-Myers Squibb"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Nivolumab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Nivolumab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Nivolumab","moa":"PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Ozanimod Hydrochloride","moa":"S1P receptor","graph1":"Neurology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"Idecabtagene vicleucel","moa":"B-Cell maturation antigen","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"NeoImmuneTech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Collaboration","leadProduct":"Nivolumab","moa":"IL-7","graph1":"Oncology","graph2":"Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Bristol Myers Squibb \/ NeoImmuneTech","highestDevelopmentStatusID":"8","companyTruncated":"Bristol Myers Squibb \/ NeoImmuneTech"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Nivolumab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Intensity Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Collaboration","leadProduct":"Cisplatin","moa":"DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Bristol Myers Squibb \/ Intensity Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Bristol Myers Squibb \/ Intensity Therapeutics"},{"orgOrder":0,"company":"Turning Point Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Repotrectinib","moa":"ROS1","graph1":"Oncology","graph2":"Phase II","graph3":"Turning Point Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Turning Point Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Turning Point Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Nivolumab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Nivolumab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Azacitidine","moa":"DNA","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Bluebird Bio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Collaboration","leadProduct":"Idecabtagene vicleucel","moa":"B-Cell maturation antigen","graph1":"Oncology","graph2":"Phase III","graph3":"Bristol Myers Squibb","amount2":0.20000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.20000000000000001,"dosageForm":"","sponsorNew":"Bristol Myers Squibb \/ Bristol Myers Squibb","highestDevelopmentStatusID":"10","companyTruncated":"Bristol Myers Squibb \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"Idecabtagene vicleucel","moa":"B-Cell maturation antigen","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Ipilimumab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Luspatercept","moa":"TGF beta","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"Idecabtagene vicleucel","moa":"B-Cell maturation antigen","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"MyoKardia","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Mavacamten","moa":"Cardiac Myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"MyoKardia","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"MyoKardia \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"MyoKardia \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Repare Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Bristol Myers Squibb","amount2":3.0699999999999998,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":3.0699999999999998,"dosageForm":"","sponsorNew":"Bristol Myers Squibb \/ Bristol Myers Squibb","highestDevelopmentStatusID":"3","companyTruncated":"Bristol Myers Squibb \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Turning Point Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"TPX-0046","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Turning Point Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Turning Point Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Turning Point Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Jounce Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Termination","leadProduct":"JTX-8064","moa":"LILRB2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Bristol Myers Squibb \/ Bristol Myers Squibb","highestDevelopmentStatusID":"6","companyTruncated":"Bristol Myers Squibb \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Ozanimod Hydrochloride","moa":"S1P receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"UbiVac","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"BMS-986178","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Bristol Myers Squibb \/ Bristol Myers Squibb","highestDevelopmentStatusID":"6","companyTruncated":"Bristol Myers Squibb \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Nivolumab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Ubiquigent","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Bristol Myers Squibb \/ Bristol Myers Squibb","highestDevelopmentStatusID":"3","companyTruncated":"Bristol Myers Squibb \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"MyoKardia","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Danicamtiv","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"MyoKardia","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"MyoKardia \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"MyoKardia \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Dragonfly Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Licensing Agreement","leadProduct":"NK cell Engager Therapies","moa":"","graph1":"Immunology","graph2":"Discovery","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Bristol Myers Squibb \/ Bristol Myers Squibb","highestDevelopmentStatusID":"2","companyTruncated":"Bristol Myers Squibb \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Luspatercept","moa":"TGF beta","graph1":"Hematology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Turning Point Therapeutics","sponsor":"Zai Lab","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Repotrectinib","moa":"TYK","graph1":"Oncology","graph2":"Phase II","graph3":"Turning Point Therapeutics","amount2":0.17999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.17999999999999999,"dosageForm":"","sponsorNew":"Turning Point Therapeutics \/ Zai Lab","highestDevelopmentStatusID":"8","companyTruncated":"Turning Point Therapeutics \/ Zai Lab"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Natco Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"INDIA","productType":"Small molecule","year":"2020","type":"Agreement","leadProduct":"Lenalidomide","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Bristol Myers Squibb \/ Bristol-Myers Squibb","highestDevelopmentStatusID":"10","companyTruncated":"Bristol Myers Squibb \/ Bristol-Myers Squibb"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"Lisocabtagene maraleucel","moa":"CD19","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"MyoKardia","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Mavacamten","moa":"Cardiac Myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"MyoKardia","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"MyoKardia \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"MyoKardia \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"Idecabtagene vicleucel","moa":"B-Cell maturation antigen","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"MyoKardia","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Mavacamten","moa":"Cardiac Myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"MyoKardia","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"MyoKardia \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"MyoKardia \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Nivolumab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"Lisocabtagene maraleucel","moa":"CD19","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Dragonfly Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Licensing Agreement","leadProduct":"DF-1001","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bristol Myers Squibb","amount2":0.01,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"","sponsorNew":"Bristol Myers Squibb \/ Bristol-Myers Squibb","highestDevelopmentStatusID":"7","companyTruncated":"Bristol Myers Squibb \/ Bristol-Myers Squibb"},{"orgOrder":0,"company":"MyoKardia","sponsor":"LianBio","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Collaboration","leadProduct":"Mavacamten","moa":"Cardiac Myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"MyoKardia","amount2":0.19,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.19,"dosageForm":"Capsule","sponsorNew":"MyoKardia \/ LianBio","highestDevelopmentStatusID":"10","companyTruncated":"MyoKardia \/ LianBio"},{"orgOrder":0,"company":"MyoKardia","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Mavacamten","moa":"Cardiac Myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"MyoKardia","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"MyoKardia \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"MyoKardia \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Nivolumab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Forbius","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Acquisition","leadProduct":"AVID200","moa":"TGF beta-1","graph1":"Oncology","graph2":"Phase I","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Bristol Myers Squibb \/ Bristol Myers Squibb","highestDevelopmentStatusID":"6","companyTruncated":"Bristol Myers Squibb \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Turning Point Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Repotrectinib","moa":"TYK","graph1":"Oncology","graph2":"Phase II","graph3":"Turning Point Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Turning Point Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Turning Point Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Turning Point Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Repotrectinib","moa":"TYK","graph1":"Oncology","graph2":"Phase II","graph3":"Turning Point Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Turning Point Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Turning Point Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Enasidenib","moa":"Isocitrate dehydrogenase","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Azacitidine","moa":"DNA","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"VBL Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"Nivolumab","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Bristol Myers Squibb","highestDevelopmentStatusID":"8","companyTruncated":"Bristol Myers Squibb \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Forbius","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Acquisition","leadProduct":"AVID200","moa":"TGF beta-1","graph1":"Oncology","graph2":"Phase I","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Bristol Myers Squibb \/ Bristol Myers Squibb","highestDevelopmentStatusID":"6","companyTruncated":"Bristol Myers Squibb \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Nivolumab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Intensity Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Cisplatin","moa":"DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Bristol Myers Squibb \/ Bristol Myers Squibb","highestDevelopmentStatusID":"7","companyTruncated":"Bristol Myers Squibb \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Nivolumab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Anokion SA","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Large molecule","year":"2020","type":"Collaboration","leadProduct":"KAN-101","moa":"","graph1":"Immunology","graph2":"Phase I","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Bristol Myers Squibb \/ Bristol Myers Squibb","highestDevelopmentStatusID":"6","companyTruncated":"Bristol Myers Squibb \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"MyoKardia","sponsor":"Fulcrum Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Genetic Disease","graph2":"Discovery","graph3":"MyoKardia","amount2":0.46999999999999997,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","amount2New":0.46999999999999997,"dosageForm":"","sponsorNew":"MyoKardia \/ MyoKardia","highestDevelopmentStatusID":"2","companyTruncated":"MyoKardia \/ MyoKardia"},{"orgOrder":0,"company":"MyoKardia","sponsor":"BofA Securities","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Public Offering","leadProduct":"Mavacamten","moa":"Cardiac Myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"MyoKardia","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"MyoKardia \/ BofA Securities","highestDevelopmentStatusID":"10","companyTruncated":"MyoKardia \/ BofA Securities"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Exelixis","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Cabozantinib","moa":"VEGFR2","graph1":"Oncology","graph2":"Phase III","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bristol Myers Squibb \/ Exelixis","highestDevelopmentStatusID":"10","companyTruncated":"Bristol Myers Squibb \/ Exelixis"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Nivolumab","moa":"PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Nivolumab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Fedratinib","moa":"FLT3","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Nivolumab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Bluebird Bio","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"Idecabtagene vicleucel","moa":"B-Cell maturation antigen","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ bluebird bio","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ bluebird bio"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Nivolumab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Ono Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Nivolumab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Bristol-Myers Squibb","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Bristol-Myers Squibb"},{"orgOrder":0,"company":"MyoKardia","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Danicamtiv","moa":"Cardiac Myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"MyoKardia","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"MyoKardia \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"MyoKardia \/ Not Applicable"},{"orgOrder":0,"company":"MyoKardia","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Mavacamten","moa":"Cardiac Myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"MyoKardia","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"MyoKardia \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"MyoKardia \/ Not Applicable"},{"orgOrder":0,"company":"MyoKardia","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Mavacamten","moa":"Cardiac Myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"MyoKardia","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"MyoKardia \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"MyoKardia \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"MyoKardia","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Acquisition","leadProduct":"Mavacamten","moa":"Cardiac Myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Bristol Myers Squibb","amount2":13.1,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":13.1,"dosageForm":"Capsule","sponsorNew":"Bristol Myers Squibb \/ Bristol Myers Squibb","highestDevelopmentStatusID":"10","companyTruncated":"Bristol Myers Squibb \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Luspatercept","moa":"TGF beta","graph1":"Hematology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Ozanimod Hydrochloride","moa":"Sphingosine 1-phosphate receptor Edg-1","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Nivolumab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Ozanimod Hydrochloride","moa":"S1PR","graph1":"Neurology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Turning Point Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"TPX-0022","moa":"CSF1R","graph1":"Oncology","graph2":"Phase I","graph3":"Turning Point Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Turning Point Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Turning Point Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Ozanimod Hydrochloride","moa":"S1P receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Nivolumab","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Cabozantinib","moa":"VEGFR2","graph1":"Oncology","graph2":"Phase III","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Turning Point Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Repotrectinib","moa":"TYK","graph1":"Oncology","graph2":"Phase II","graph3":"Turning Point Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Turning Point Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Turning Point Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Insitro","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Neurology","graph2":"Discovery","graph3":"Bristol Myers Squibb","amount2":2.1000000000000001,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":2.1000000000000001,"dosageForm":"","sponsorNew":"Bristol Myers Squibb \/ Bristol Myers Squibb","highestDevelopmentStatusID":"2","companyTruncated":"Bristol Myers Squibb \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"MyoKardia","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Mavacamten","moa":"Cardiac Myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"MyoKardia","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"MyoKardia \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"MyoKardia \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Deucravacitinib","moa":"TYK2","graph1":"Dermatology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Deucravacitinib","moa":"TYK2","graph1":"Immunology","graph2":"Phase III","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Nivolumab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"MyoKardia","sponsor":"MyoKardia","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Collaboration","leadProduct":"Mavacamten","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"MyoKardia","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"","sponsorNew":"MyoKardia \/ MyoKardia","highestDevelopmentStatusID":"10","companyTruncated":"MyoKardia \/ MyoKardia"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Infinity Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Eganelisib","moa":"PI3K gamma","graph1":"Oncology","graph2":"Phase I","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Bristol Myers Squibb \/ Bristol Myers Squibb","highestDevelopmentStatusID":"6","companyTruncated":"Bristol Myers Squibb \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Deucravacitinib","moa":"TYK2","graph1":"Immunology","graph2":"Phase III","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Ikena Oncology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"IK-175","moa":"Aryl hydrocarbon receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Bristol Myers Squibb \/ Bristol Myers Squibb","highestDevelopmentStatusID":"6","companyTruncated":"Bristol Myers Squibb \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Kitov Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"CM-24","moa":"CEACAM1","graph1":"Oncology","graph2":"Undisclosed","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bristol Myers Squibb \/ Bristol Myers Squibb","highestDevelopmentStatusID":"1","companyTruncated":"Bristol Myers Squibb \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"MyoKardia","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Acquisition","leadProduct":"Mavacamten","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Bristol Myers Squibb","amount2":13.1,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":13.1,"dosageForm":"","sponsorNew":"Bristol Myers Squibb \/ Bristol Myers Squibb","highestDevelopmentStatusID":"10","companyTruncated":"Bristol Myers Squibb \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"MyoKardia","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Mavacamten","moa":"Cardiac Myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"MyoKardia","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"MyoKardia \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"MyoKardia \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Schrodinger","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"HIF-2 alpha","graph1":"Oncology","graph2":"Discovery","graph3":"Bristol Myers Squibb","amount2":2.7599999999999998,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":2.7599999999999998,"dosageForm":"","sponsorNew":"Bristol Myers Squibb \/ Bristol Myers Squibb","highestDevelopmentStatusID":"2","companyTruncated":"Bristol Myers Squibb \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Ono Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Nivolumab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Bristol Myers Squibb \/ Ono Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Ono Pharmaceutical"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Bluebird Bio","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"Idecabtagene vicleucel","moa":"B-Cell maturation antigen","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Bluebird Bio","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Bluebird Bio"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"Lisocabtagene maraleucel","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Azacitidine","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Turning Point Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Repotrectinib","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Turning Point Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"capsule","sponsorNew":"Turning Point Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Turning Point Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Fedratinib","moa":"JAK2","graph1":"Oncology","graph2":"Phase III","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Nivolumab","moa":"PD-L1","graph1":"Oncology","graph2":"Phase IV","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"11","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"ArsenalBio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Collaboration","leadProduct":"Next-generation T cell therapies","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Bristol Myers Squibb \/ Bristol Myers Squibb","highestDevelopmentStatusID":"2","companyTruncated":"Bristol Myers Squibb \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Not Applicable","leadProduct":"Lisocabtagene maraleucel","moa":"CD19","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Nivolumab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Nivolumab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Nivolumab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous solution","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Turning Point Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Repotrectinib","moa":"ROS1","graph1":"Oncology","graph2":"Phase II","graph3":"Turning Point Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Turning Point Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Turning Point Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Collaboration","leadProduct":"C-135-LS","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Bristol Myers Squibb \/ Bristol Myers Squibb","highestDevelopmentStatusID":"6","companyTruncated":"Bristol Myers Squibb \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Molecular Templates","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Bristol Myers Squibb","amount2":1.3700000000000001,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":1.3700000000000001,"dosageForm":"","sponsorNew":"Bristol Myers Squibb \/ Bristol Myers Squibb","highestDevelopmentStatusID":"3","companyTruncated":"Bristol Myers Squibb \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Ozanimod Hydrochloride","moa":"S1P receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Deucravacitinib","moa":"TYK2","graph1":"Dermatology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Not Applicable","leadProduct":"Orvacabtagene autoleucel","moa":"T lymphocyte","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Compugen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Collaboration","leadProduct":"COM701","moa":"PVRIG","graph1":"Oncology","graph2":"Phase I","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Compugen","highestDevelopmentStatusID":"6","companyTruncated":"Bristol Myers Squibb \/ Compugen"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Not Applicable","leadProduct":"Lisocabtagene maraleucel","moa":"CD19","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Bluebird Bio","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Not Applicable","leadProduct":"Idecabtagene Vicleucel","moa":"B-Cell maturation antigen","graph1":"Oncology","graph2":"Phase III","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Bristol Myers Squibb","highestDevelopmentStatusID":"10","companyTruncated":"Bristol Myers Squibb \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Ipsen","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Cabozantinib","moa":"VEGFR2","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bristol Myers Squibb \/ Bristol Myers Squibb","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Aveo Oncology","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"INDIA","productType":"Small molecule","year":"2021","type":"Collaboration","leadProduct":"Tivozanib","moa":"VEGFR 1","graph1":"Oncology","graph2":"Phase III","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"capsule","sponsorNew":"Bristol Myers Squibb \/ Bristol Myers Squibb","highestDevelopmentStatusID":"10","companyTruncated":"Bristol Myers Squibb \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"MyoKardia","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Mavacamten","moa":"Cardiac Myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"MyoKardia","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"MyoKardia \/ MyoKardia","highestDevelopmentStatusID":"12","companyTruncated":"MyoKardia \/ MyoKardia"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Idera Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Ipilimumab","moa":"TLR9","graph1":"Oncology","graph2":"Phase III","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Bristol Myers Squibb \/ Bristol-Myers Squibb","highestDevelopmentStatusID":"10","companyTruncated":"Bristol Myers Squibb \/ Bristol-Myers Squibb"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Nivolumab","moa":"LAG3","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Akamis Bio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Collaboration","leadProduct":"NG-641","moa":"AP\/CD3","graph1":"Oncology","graph2":"IND Enabling","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Bristol Myers Squibb \/ PsiOxus Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Bristol Myers Squibb \/ PsiOxus Therapeutics"},{"orgOrder":0,"company":"Turning Point Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"TPX-0131","moa":"Anaplastic lymphoma kinase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Turning Point Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Turning Point Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Turning Point Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Nivolumab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Evotec","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Protein degradation","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Bristol Myers Squibb \/ Bristol Myers Squibb","highestDevelopmentStatusID":"3","companyTruncated":"Bristol Myers Squibb \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Nivolumab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Deucravacitinib","moa":"TYK2","graph1":"Dermatology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Azacitidine","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Nivolumab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Syngene International Limited","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"INDIA","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Bristol Myers Squibb \/ Bristol Myers Squibb","highestDevelopmentStatusID":"2","companyTruncated":"Bristol Myers Squibb \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Mavacamten","moa":"Cardiac Myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Nivolumab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Nivolumab","moa":"LAG3","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Agenus","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Licensing Agreement","leadProduct":"AGEN1777","moa":"TIGIT","graph1":"Oncology","graph2":"Phase I","graph3":"Bristol Myers Squibb","amount2":1.5600000000000001,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":1.5600000000000001,"dosageForm":"","sponsorNew":"Bristol Myers Squibb \/ Bristol Myers","highestDevelopmentStatusID":"6","companyTruncated":"Bristol Myers Squibb \/ Bristol Myers"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Exscientia","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Small molecule","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Bristol Myers Squibb","amount2":1.3799999999999999,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":1.3799999999999999,"dosageForm":"","sponsorNew":"Bristol Myers Squibb \/ Bristol Myers Squibb","highestDevelopmentStatusID":"6","companyTruncated":"Bristol Myers Squibb \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Xencor","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Licensing Agreement","leadProduct":"C-135-LS","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Bristol Myers Squibb \/ Bristol Myers Squibb","highestDevelopmentStatusID":"9","companyTruncated":"Bristol Myers Squibb \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Nivolumab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Nivolumab","moa":"LAG3","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Nivolumab","moa":"LAG3","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Ozanimod Hydrochloride","moa":"S1P receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Ono Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Nivolumab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Bristol-Myers Squibb","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Bristol-Myers Squibb"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Ozanimod Hydrochloride","moa":"S1P receptor","graph1":"Gastroenterology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Exelixis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Collaboration","leadProduct":"Encoberminogene Rezmadenovec","moa":"TYK","graph1":"Oncology","graph2":"Phase I","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Bristol Myers Squibb \/ Exelixis","highestDevelopmentStatusID":"6","companyTruncated":"Bristol Myers Squibb \/ Exelixis"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Nivolumab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Nivolumab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Nivolumab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Compugen","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"COM701","moa":"PVRIG","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Bristol-Myers Squibb","highestDevelopmentStatusID":"7","companyTruncated":"Bristol Myers Squibb \/ Bristol-Myers Squibb"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Deucravacitinib","moa":"TYK2","graph1":"Immunology","graph2":"Phase III","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Acceleron Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Luspatercept","moa":"TGF beta","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Bristol Myers Squibb \/ Acceleron Pharma Inc.","highestDevelopmentStatusID":"8","companyTruncated":"Bristol Myers Squibb \/ Acceleron Pharma Inc."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Eisai","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"JAPAN","productType":"Large molecule","year":"2021","type":"Collaboration","leadProduct":"Eribulin","moa":"Folate receptor alpha","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bristol Myers Squibb","amount2":3.1000000000000001,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":3.1000000000000001,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Bristol Myers Squibb","highestDevelopmentStatusID":"7","companyTruncated":"Bristol Myers Squibb \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Celgene Corporation","sponsor":"Sun Pharmaceutical Industries Limited","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Agreement","leadProduct":"Lenalidomide","moa":"Cereblon","graph1":"Oncology","graph2":"Approved","graph3":"Celgene Corporation","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Celgene Corporation \/ Sun Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Celgene Corporation \/ Sun Pharma"},{"orgOrder":0,"company":"Turning Point Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"TPX0022","moa":"CSF1R","graph1":"Oncology","graph2":"Phase I","graph3":"Turning Point Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Turning Point Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Turning Point Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Azacitidine","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Nivolumab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Nivolumab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Turning Point Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Repotrectinib","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Turning Point Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Turning Point Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Turning Point Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Agenus","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Licensing Agreement","leadProduct":"AGEN1777","moa":"TIGIT","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bristol Myers Squibb","amount2":1.5600000000000001,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":1.5600000000000001,"dosageForm":"","sponsorNew":"Bristol Myers Squibb \/ Bristol Myers Squibb","highestDevelopmentStatusID":"7","companyTruncated":"Bristol Myers Squibb \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Nivolumab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"BridgeBio Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Collaboration","leadProduct":"BBP-398","moa":"SHP2","graph1":"Oncology","graph2":"IND Enabling","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Bristol Myers Squibb \/ BridgeBio","highestDevelopmentStatusID":"5","companyTruncated":"Bristol Myers Squibb \/ BridgeBio"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Compugen","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"BMS-986207","moa":"PVRIG","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Bristol-Myers Squibb","highestDevelopmentStatusID":"7","companyTruncated":"Bristol Myers Squibb \/ Bristol-Myers Squibb"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Nivolumab","moa":"PD-1","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Romidepsin","moa":"HDAC","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Exscientia","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Small molecule","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"kinase","graph1":"Immunology","graph2":"Discovery Platform","graph3":"Bristol Myers Squibb","amount2":1.2,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Immunology","amount2New":1.2,"dosageForm":"","sponsorNew":"Bristol Myers Squibb \/ Bristol Myers Squibb","highestDevelopmentStatusID":"3","companyTruncated":"Bristol Myers Squibb \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Turning Point Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Repotrectinib","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Turning Point Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Turning Point Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Turning Point Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Apixaban","moa":"Factor Xa","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2021","type":"Not Applicable","leadProduct":"Idecabtagene Vicleucel","moa":"B-Cell maturation antigen","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Dispersion for Infusion","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Not Applicable","leadProduct":"Abatacept","moa":"","graph1":"Immunology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Abatacept","moa":"","graph1":"Immunology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Nivolumab","moa":"LAG3","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Ono Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Nivolumab","moa":"PD-1","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Bristol Myers Squibb \/ Ono Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Ono Pharma"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Nivolumab","moa":"LAG3","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Agenus","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Licensing Agreement","leadProduct":"AGEN1777","moa":"TIGIT","graph1":"Oncology","graph2":"Phase I","graph3":"Bristol Myers Squibb","amount2":1.5800000000000001,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":1.5800000000000001,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Bristol Myers Squibb","highestDevelopmentStatusID":"6","companyTruncated":"Bristol Myers Squibb \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Evotec","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Expanded Collaboration","leadProduct":"iPSC-based Cell Therapy","moa":"","graph1":"Neurology","graph2":"Discovery","graph3":"Bristol Myers Squibb","amount2":0.28000000000000003,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0.28000000000000003,"dosageForm":"","sponsorNew":"Bristol Myers Squibb \/ Evotec","highestDevelopmentStatusID":"2","companyTruncated":"Bristol Myers Squibb \/ Evotec"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Evotec","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"GERMANY","productType":"Small molecule","year":"2021","type":"Collaboration","leadProduct":"EVT8683","moa":"","graph1":"Neurology","graph2":"IND Enabling","graph3":"Bristol Myers Squibb","amount2":0.27000000000000002,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"Bristol Myers Squibb \/ Bristol Myers Squibb","highestDevelopmentStatusID":"5","companyTruncated":"Bristol Myers Squibb \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Nivolumab","moa":"LAG3","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Turning Point Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Repotrectinib","moa":"TYK","graph1":"Oncology","graph2":"Phase II","graph3":"Turning Point Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Turning Point Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Turning Point Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Turning Point Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Elzovantinib","moa":"MET\/SRC\/CSF1R","graph1":"Oncology","graph2":"Phase I","graph3":"Turning Point Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Turning Point Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Turning Point Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Deucravacitinib","moa":"TYK2","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Ozanimod Hydrochloride","moa":"S1P receptor","graph1":"Gastroenterology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"TCR2 Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Collaboration","leadProduct":"Gavocabtagene Autoleucel","moa":"Mesothelin","graph1":"Oncology","graph2":"Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Bristol Myers Squibb \/ TCR2 Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Bristol Myers Squibb \/ TCR2 Therapeutics"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Ubiquigent","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Bristol Myers Squibb \/ Ubiquigent Limited","highestDevelopmentStatusID":"3","companyTruncated":"Bristol Myers Squibb \/ Ubiquigent Limited"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Nivolumab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Turning Point Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Repotrectinib","moa":"TYK","graph1":"Oncology","graph2":"Phase II","graph3":"Turning Point Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Turning Point Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Turning Point Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Turning Point Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Repotrectinib","moa":"TYK","graph1":"Oncology","graph2":"Phase II","graph3":"Turning Point Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Turning Point Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Turning Point Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Evotec","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"GERMANY","productType":"Small molecule","year":"2021","type":"Collaboration","leadProduct":"EVT8683","moa":"","graph1":"Neurology","graph2":"IND Enabling","graph3":"Bristol Myers Squibb","amount2":0.040000000000000001,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"Bristol Myers Squibb \/ Bristol Myers Squibb","highestDevelopmentStatusID":"5","companyTruncated":"Bristol Myers Squibb \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Compugen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Large molecule","year":"2021","type":"Expanded Collaboration","leadProduct":"BMS-986207","moa":"PVRIG","graph1":"Oncology","graph2":"Phase II","graph3":"Bristol Myers Squibb","amount2":0.02,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"Intravenous","sponsorNew":"Bristol Myers Squibb \/ Bristol Myers Squibb","highestDevelopmentStatusID":"8","companyTruncated":"Bristol Myers Squibb \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Abatacept","moa":"GMP-AMP synthase","graph1":"Immunology","graph2":"Undisclosed","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Nivolumab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Mavacamten","moa":"Cardiac Myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bristol Myers Squibb \/ Janssen","highestDevelopmentStatusID":"10","companyTruncated":"Bristol Myers Squibb \/ Janssen"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"UNITED KINGDOM","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Milvexian","moa":"Factor XIa","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bristol Myers Squibb \/ Janssen Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Bristol Myers Squibb \/ Janssen Pharmaceuticals"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"InveniAI","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Rare Diseases and Disorders","graph2":"Discovery","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Dosage Strength\/Form","sponsorNew":"Bristol Myers Squibb \/ Bristol Myers Squibb","highestDevelopmentStatusID":"2","companyTruncated":"Bristol Myers Squibb \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Mavacamten","moa":"Cardiac Myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Ozanimod Hydrochloride","moa":"S1P receptor","graph1":"Gastroenterology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Deucravacitinib","moa":"TYK2","graph1":"Dermatology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Immatics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Large molecule","year":"2021","type":"Licensing Agreement","leadProduct":"IMA401","moa":"MAGEA4\/8","graph1":"Oncology","graph2":"Phase I","graph3":"Bristol Myers Squibb","amount2":0.92000000000000004,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.92000000000000004,"dosageForm":"Dosage Strength\/Form","sponsorNew":"Bristol Myers Squibb \/ Bristol Myers Squibb","highestDevelopmentStatusID":"6","companyTruncated":"Bristol Myers Squibb \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Bolt Biotherapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Nivolumab","moa":"HER2 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Bristol Myers Squibb \/ Bristol Myers Squibb","highestDevelopmentStatusID":"7","companyTruncated":"Bristol Myers Squibb \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Luspatercept","moa":"TGF beta","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Not Applicable","leadProduct":"Lisocabtagene Maraleucel","moa":"CD19","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Abatacept","moa":"GMP-AMP synthase","graph1":"Immunology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Prellis Biologics","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Collaboration","leadProduct":"Antibody","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Bristol Myers Squibb \/ Bristol Myers Squibb","highestDevelopmentStatusID":"3","companyTruncated":"Bristol Myers Squibb \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Bolt Biotherapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Nivolumab","moa":"HER2 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Bristol Myers Squibb \/ Bristol Myers Squibb","highestDevelopmentStatusID":"7","companyTruncated":"Bristol Myers Squibb \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"Lisocabtagene Maraleucel","moa":"CD19","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Evotec","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"GERMANY","productType":"Undisclosed","year":"2022","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"Protein","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Bristol Myers Squibb","amount2":0.28999999999999998,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":0.28999999999999998,"dosageForm":"","sponsorNew":"Bristol Myers Squibb \/ Bristol Myers Squibb","highestDevelopmentStatusID":"3","companyTruncated":"Bristol Myers Squibb \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Exelixis","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Nivolumab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Bristol Myers Squibb \/ Exelixis","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Exelixis"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"Lisocabtagene Maraleucel","moa":"CD19","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"Idecabtagene Vicleucel","moa":"B-Cell maturation antigen","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Biohaven Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Taldefgrobep Alfa","moa":"Myostatin activation","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"Bristol Myers Squibb \/ Biohaven Pharmaceutical","highestDevelopmentStatusID":"6","companyTruncated":"Bristol Myers Squibb \/ Biohaven Pharmaceutical"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Nivolumab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Nivolumab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Nivolumab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Nivolumab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Dragonfly Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"BMS-9896415","moa":"IL-12 fusion protein","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Bristol Myers Squibb \/ BMS","highestDevelopmentStatusID":"7","companyTruncated":"Bristol Myers Squibb \/ BMS"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Teva Pharmaceutical Industries","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Lenalidomide","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bristol Myers Squibb \/ Bristol Myers Squibb","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Nivolumab","moa":"PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Nektar Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Bempegaldesleukin","moa":"IL-2 beta receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Bristol Myers Squibb \/ Nektar","highestDevelopmentStatusID":"10","companyTruncated":"Bristol Myers Squibb \/ Nektar"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Transcenta Holding","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Collaboration","leadProduct":"Nivolumab","moa":"CLDN18.2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Bristol Myers Squibb \/ Transcenta","highestDevelopmentStatusID":"7","companyTruncated":"Bristol Myers Squibb \/ Transcenta"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Nivolumab","moa":"PD-1","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Turning Point Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Repotrectinib","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Turning Point Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Turning Point Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Turning Point Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"MyoKardia","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Mavacamten","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"MyoKardia","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"MyoKardia \/ MyoKardia","highestDevelopmentStatusID":"12","companyTruncated":"MyoKardia \/ MyoKardia"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Luspatercept","moa":"TGF beta","graph1":"Genetic Disease","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Nivolumab","moa":"PD-1","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"Lisocabtagene Maraleucel","moa":"CD19","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"New York Heart Association","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Mavacamten","moa":"Cardiac Myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bristol Myers Squibb \/ New York Heart Association","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ New York Heart Association"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Mavacamten","moa":"Cardiac Myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"Lisocabtagene Maraleucel","moa":"CD19","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Nivolumab","moa":"PD-1","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Nivolumab","moa":"PD-1","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Gritstone bio","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"GRT-C903","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Bristol Myers Squibb \/ Bristol-Myers Squibb","highestDevelopmentStatusID":"7","companyTruncated":"Bristol Myers Squibb \/ Bristol-Myers Squibb"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Nektar Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Bempegaldesleukin","moa":"IL-2","graph1":"Oncology","graph2":"Phase III","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Bristol Myers Squibb","highestDevelopmentStatusID":"10","companyTruncated":"Bristol Myers Squibb \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Nivolumab","moa":"PD-1","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Turning Point Therapeutics","sponsor":"Zai Lab","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Repotrectinib","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Turning Point Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Turning Point Therapeutics \/ Zai Lab","highestDevelopmentStatusID":"8","companyTruncated":"Turning Point Therapeutics \/ Zai Lab"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Mavacamten","moa":"Cardiac Myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Turning Point Therapeutics","sponsor":"LaNova Medicines","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ITALY","productType":"Large molecule","year":"2022","type":"Licensing Agreement","leadProduct":"LM-302","moa":"Claudin18.2","graph1":"Oncology","graph2":"Phase I","graph3":"Turning Point Therapeutics","amount2":0.22,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.22,"dosageForm":"Injection","sponsorNew":"Turning Point Therapeutics \/ Turning Point Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Turning Point Therapeutics \/ Turning Point Therapeutics"},{"orgOrder":0,"company":"MyoKardia","sponsor":"LianBio","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Mavacamten","moa":"Cardiac Myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"MyoKardia","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"","sponsorNew":"MyoKardia \/ MyoKardia","highestDevelopmentStatusID":"12","companyTruncated":"MyoKardia \/ MyoKardia"},{"orgOrder":0,"company":"Turning Point Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Repotrectinib","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Turning Point Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Turning Point Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Turning Point Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Deucravacitinib","moa":"TYK2","graph1":"Dermatology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"Lisocabtagene Maraleucel","moa":"CD19","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Nivolumab","moa":"PD-1","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"Lisocabtagene Maraleucel","moa":"CD19","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Nivolumab","moa":"PD-1","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Farletuzumab Ecteribulin","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bristol Myers Squibb \/ Bristol Myers Squibb","highestDevelopmentStatusID":"7","companyTruncated":"Bristol Myers Squibb \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Nivolumab","moa":"PD-1","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Nivolumab","moa":"PD-1","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Pyxis Oncology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Sotigalimab","moa":"CD40","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Bristol Myers Squibb \/ Bristol-Myers Squibb","highestDevelopmentStatusID":"7","companyTruncated":"Bristol Myers Squibb \/ Bristol-Myers Squibb"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Acceleron Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Luspatercept","moa":"TGF beta","graph1":"Genetic Disease","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Bristol Myers Squibb \/ Acceleron Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Acceleron Pharma"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Deucravacitinib","moa":"TYK2","graph1":"Immunology","graph2":"Phase III","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Abatacept","moa":"GMP-AMP synthase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"Lisocabtagene Maraleucel","moa":"CD19","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Ozanimod Hydrochloride","moa":"Sphingosine 1-phosphate receptor Edg-1","graph1":"Neurology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"Lisocabtagene Maraleucel","moa":"CD19","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"CytomX Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"BMS-986249","moa":"CTLA-4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Bristol Myers Squibb \/ Bristol Myers Squibb","highestDevelopmentStatusID":"7","companyTruncated":"Bristol Myers Squibb \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Ono Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Nivolumab","moa":"LAG3 receptor","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Bristol Myers Squibb \/ Ono Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Ono Pharmaceutical"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Biomica","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"BMC128","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Bristol Myers Squibb \/ Bristol Myers Squibb","highestDevelopmentStatusID":"6","companyTruncated":"Bristol Myers Squibb \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Turning Point Therapeutics","sponsor":"Zai Lab","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Repotrectinib","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Turning Point Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Turning Point Therapeutics \/ Zai Lab","highestDevelopmentStatusID":"8","companyTruncated":"Turning Point Therapeutics \/ Zai Lab"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Nivolumab","moa":"PD-1","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"2Seventy Bio","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"Idecabtagene Vicleucel","moa":"B-Cell maturation antigen","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bristol Myers Squibb \/ 2seventy bio","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ 2seventy bio"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Gritstone bio","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"GRT-C901","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Bristol Myers Squibb \/ Bristol-Myers Squibb","highestDevelopmentStatusID":"7","companyTruncated":"Bristol Myers Squibb \/ Bristol-Myers Squibb"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Turning Point Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Acquisition","leadProduct":"Repotrectinib","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Bristol Myers Squibb","amount2":4.0999999999999996,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":4.0999999999999996,"dosageForm":"Capsule","sponsorNew":"Bristol Myers Squibb \/ Bristol Myers Squibb","highestDevelopmentStatusID":"8","companyTruncated":"Bristol Myers Squibb \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Milvexian","moa":"FXIa","graph1":"Neurology","graph2":"Phase III","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bristol Myers Squibb \/ Janssen Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Bristol Myers Squibb \/ Janssen Pharmaceutical"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Nivolumab","moa":"LAG3 receptor","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Deucravacitinib","moa":"TYK2","graph1":"Dermatology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Deucravacitinib","moa":"TYK2","graph1":"Dermatology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Gritstone bio","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"GRT-C903","moa":"CD8 positve cytotoxic T Cell","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Bristol Myers Squibb \/ Bristol Myers Squibb","highestDevelopmentStatusID":"7","companyTruncated":"Bristol Myers Squibb \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Nivolumab","moa":"LAG3 receptor","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Nivolumab","moa":"LAG3 receptor","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"TCR2 Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"Gavocabtagene Autoleucel","moa":"CD3E subunit","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Bristol Myers Squibb \/ Bristol-Myers Squibb","highestDevelopmentStatusID":"7","companyTruncated":"Bristol Myers Squibb \/ Bristol-Myers Squibb"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Autolus Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2022","type":"Agreement","leadProduct":"CAR-T Cell Therapy","moa":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Bristol Myers Squibb \/ Bristol Myers Squibb","highestDevelopmentStatusID":"1","companyTruncated":"Bristol Myers Squibb \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"SyntheX labs","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Bristol Myers Squibb","amount2":0.55000000000000004,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0.55000000000000004,"dosageForm":"","sponsorNew":"Bristol Myers Squibb \/ Bristol Myers Squibb","highestDevelopmentStatusID":"3","companyTruncated":"Bristol Myers Squibb \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Exelixis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Collaboration","leadProduct":"Encoberminogene Rezmadenovec","moa":"TYK","graph1":"Oncology","graph2":"Phase I","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Bristol Myers Squibb \/ Bristol Myers Squibb","highestDevelopmentStatusID":"6","companyTruncated":"Bristol Myers Squibb \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Compugen","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"COM701","moa":"PVRIG","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Bristol Myers Squibb \/ Bristol Myers Squibb","highestDevelopmentStatusID":"7","companyTruncated":"Bristol Myers Squibb \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Nivolumab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Mavacamten","moa":"Cardiac Myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Ozanimod Hydrochloride","moa":"S1P receptor","graph1":"Gastroenterology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Ozanimod Hydrochloride","moa":"S1P receptor","graph1":"Neurology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Luspatercept","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"PicnicHealth","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Mavacamten","moa":"Cardiac Myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bristol Myers Squibb \/ Bristol Myers Squibb","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Lyvgen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Collaboration","leadProduct":"LVGN7409","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bristol Myers Squibb \/ Bristol Myers Squibb","highestDevelopmentStatusID":"4","companyTruncated":"Bristol Myers Squibb \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Replimune","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Nivolumab","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Bristol Myers Squibb \/ Bristol Myers Squibb","highestDevelopmentStatusID":"8","companyTruncated":"Bristol Myers Squibb \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"Idecabtagene Vicleucel","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Evotec","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"GERMANY","productType":"Small molecule","year":"2022","type":"Collaboration","leadProduct":"EVT8683","moa":"","graph1":"Neurology","graph2":"Discovery","graph3":"Bristol Myers Squibb","amount2":0.029999999999999999,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Bristol Myers Squibb \/ Bristol Myers Squibb","highestDevelopmentStatusID":"2","companyTruncated":"Bristol Myers Squibb \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"Lisocabtagene Maraleucel","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Lexicon pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"LX9211","moa":"AAK-1","graph1":"Neurology","graph2":"Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Bristol Myers Squibb \/ Bristol Myers Squibb","highestDevelopmentStatusID":"8","companyTruncated":"Bristol Myers Squibb \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"Ibrutinib","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Luspatercept","moa":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Deucravacitinib","moa":"","graph1":"Dermatology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Prothena","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"IRELAND","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"PRX005","moa":"","graph1":"Neurology","graph2":"Phase I","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bristol Myers Squibb \/ Bristol Myers Squibb","highestDevelopmentStatusID":"6","companyTruncated":"Bristol Myers Squibb \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Century Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Collaboration","leadProduct":"CNTY-104","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Bristol Myers Squibb","amount2":3.1499999999999999,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":3.1499999999999999,"dosageForm":"","sponsorNew":"Bristol Myers Squibb \/ Bristol Myers Squibb","highestDevelopmentStatusID":"2","companyTruncated":"Bristol Myers Squibb \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Volastra Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Bristol Myers Squibb","amount2":1.1299999999999999,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":1.1299999999999999,"dosageForm":"","sponsorNew":"Bristol Myers Squibb \/ Bristol Myers Squibb","highestDevelopmentStatusID":"4","companyTruncated":"Bristol Myers Squibb \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Amphista Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"UNITED KINGDOM","productType":"Small molecule","year":"2022","type":"Collaboration","leadProduct":"Targeted Protein Degradation Therapy","moa":"Protein","graph1":"Technology","graph2":"Discovery Platform","graph3":"Bristol Myers Squibb","amount2":1.28,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":1.28,"dosageForm":"Inhalation","sponsorNew":"Bristol Myers Squibb \/ Bristol Myers Squibb","highestDevelopmentStatusID":"3","companyTruncated":"Bristol Myers Squibb \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"BridgeBio Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Licensing Agreement","leadProduct":"BBP-398","moa":"SHP2","graph1":"Oncology","graph2":"Phase I","graph3":"Bristol Myers Squibb","amount2":0.91000000000000003,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.91000000000000003,"dosageForm":"Capsule","sponsorNew":"Bristol Myers Squibb \/ Bristol Myers Squibb","highestDevelopmentStatusID":"6","companyTruncated":"Bristol Myers Squibb \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Immatics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Cell and Gene therapy","year":"2022","type":"Collaboration","leadProduct":"CAR-T Cell Therapy","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Bristol Myers Squibb","amount2":1.46,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":1.46,"dosageForm":"","sponsorNew":"Bristol Myers Squibb \/ Bristol Myers Squibb","highestDevelopmentStatusID":"4","companyTruncated":"Bristol Myers Squibb \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"GentiBio","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Collaboration","leadProduct":"Egineered Treg Cell Therapy","moa":"Treg Cell","graph1":"Gastroenterology","graph2":"Discovery Platform","graph3":"Bristol Myers Squibb","amount2":1.8999999999999999,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Gastroenterology","amount2New":1.8999999999999999,"dosageForm":"","sponsorNew":"Bristol Myers Squibb \/ Bristol Myers Squibb","highestDevelopmentStatusID":"3","companyTruncated":"Bristol Myers Squibb \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"Idecabtagene Vicleucel","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Exelixis","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Nivolumab","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bristol Myers Squibb \/ Bristol Myers Squibb","highestDevelopmentStatusID":"10","companyTruncated":"Bristol Myers Squibb \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Nivolumab","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Nivolumab","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Milvexian","moa":"","graph1":"Neurology","graph2":"Phase III","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bristol Myers Squibb \/ Janssen Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Bristol Myers Squibb \/ Janssen Pharmaceutical"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Luspatercept","moa":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Evotec","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Small molecule","year":"2023","type":"Partnership","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Bristol Myers Squibb","amount2":5.2000000000000002,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":5.2000000000000002,"dosageForm":"","sponsorNew":"Bristol Myers Squibb \/ Bristol Myers Squibb","highestDevelopmentStatusID":"3","companyTruncated":"Bristol Myers Squibb \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"CHARM Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"UNITED KINGDOM","productType":"Small molecule","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Bristol Myers Squibb \/ Bristol Myers Squibb","highestDevelopmentStatusID":"2","companyTruncated":"Bristol Myers Squibb \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Evotec","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Small molecule","year":"2023","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Bristol Myers Squibb","amount2":5.2000000000000002,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":5.2000000000000002,"dosageForm":"","sponsorNew":"Bristol Myers Squibb \/ Bristol Myers Squibb","highestDevelopmentStatusID":"3","companyTruncated":"Bristol Myers Squibb \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Deucravacitinib","moa":"","graph1":"Dermatology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Nivolumab","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"Lisocabtagene Maraleucel","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"ConvaTec","sponsor":"30 Technology","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Small molecule","year":"2023","type":"Divestment","leadProduct":"RESP301","moa":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"ConvaTec","amount2":0.22,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.22,"dosageForm":"Inhalation Solution","sponsorNew":"ConvaTec \/ ConvaTec","highestDevelopmentStatusID":"8","companyTruncated":"ConvaTec \/ ConvaTec"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Tubulis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Large molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Antibody-drug Conjugate","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Bristol Myers Squibb","amount2":1.02,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":1.02,"dosageForm":"","sponsorNew":"Bristol Myers Squibb \/ Bristol Myers Squibb","highestDevelopmentStatusID":"4","companyTruncated":"Bristol Myers Squibb \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"2Seventy Bio","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"Idecabtagene Vicleucel","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Suspension for Infusion","sponsorNew":"Bristol Myers Squibb \/ 2seventy bio","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ 2seventy bio"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Mavacamten","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Immatics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Cell and Gene therapy","year":"2023","type":"Licensing Agreement","leadProduct":"TCR-T-based Therapy","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Bristol Myers Squibb","amount2":0.51000000000000001,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.51000000000000001,"dosageForm":"","sponsorNew":"Bristol Myers Squibb \/ Bristol Myers Squibb","highestDevelopmentStatusID":"4","companyTruncated":"Bristol Myers Squibb \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"Lisocabtagene Maraleucel","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Luspatercept","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"Lisocabtagene Maraleucel","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Suspension for Infusion","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Amphista Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"UNITED KINGDOM","productType":"Small molecule","year":"2023","type":"Collaboration","leadProduct":"Targeted Protein Degradation Therapy","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Bristol Myers Squibb","amount2":1.28,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":1.28,"dosageForm":"","sponsorNew":"Bristol Myers Squibb \/ Bristol Myers Squibb","highestDevelopmentStatusID":"3","companyTruncated":"Bristol Myers Squibb \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"BMS-986278","moa":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Milvexian","moa":"","graph1":"Neurology","graph2":"Phase III","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Nivolumab","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Repotrectinib","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"MEDIC Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Bristol Myers Squibb \/ Bristol Myers Squibb","highestDevelopmentStatusID":"2","companyTruncated":"Bristol Myers Squibb \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Nivolumab","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Mavacamten","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Aveo Oncology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Tivozanib","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bristol Myers Squibb \/ Bristol Myers Squibb","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Nivolumab","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Mavacamten","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Evotec","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"GERMANY","productType":"Undisclosed","year":"2023","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Neurology","graph2":"Discovery","graph3":"Bristol Myers Squibb","amount2":4,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":4,"dosageForm":"","sponsorNew":"Bristol Myers Squibb \/ Bristol Myers Squibb","highestDevelopmentStatusID":"2","companyTruncated":"Bristol Myers Squibb \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Prothena","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"IRELAND","productType":"Large molecule","year":"2023","type":"Collaboration","leadProduct":"PRX005","moa":"","graph1":"Neurology","graph2":"Phase I","graph3":"Bristol Myers Squibb","amount2":2.2000000000000002,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":2.2000000000000002,"dosageForm":"Infusion","sponsorNew":"Bristol Myers Squibb \/ Bristol Myers Squibb","highestDevelopmentStatusID":"6","companyTruncated":"Bristol Myers Squibb \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Nivolumab","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Nivolumab","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Immatics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Cell and Gene therapy","year":"2023","type":"Financing","leadProduct":"Nivolumab","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bristol Myers Squibb \/ Bristol Myers Squibb","highestDevelopmentStatusID":"6","companyTruncated":"Bristol Myers Squibb \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Nivolumab","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Mavacamten","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Luspatercept","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Zenas BioPharma","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Collaboration","leadProduct":"Obexelimab","moa":"","graph1":"Immunology","graph2":"Phase III","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bristol Myers Squibb \/ Bristol Myers Squibb","highestDevelopmentStatusID":"10","companyTruncated":"Bristol Myers Squibb \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Nivolumab","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Mirati Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Acquisition","leadProduct":"Adagrasib","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":5.7999999999999998,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":5.7999999999999998,"dosageForm":"Tablet, Film Coated","sponsorNew":"Bristol Myers Squibb \/ Bristol Myers Squibb","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Deucravacitinib","moa":"","graph1":"Dermatology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Nivolumab","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Nivolumab","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Nivolumab","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Nivolumab","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"LianBio","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Small molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Mavacamten","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0.34999999999999998,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.34999999999999998,"dosageForm":"Capsule","sponsorNew":"Bristol Myers Squibb \/ Bristol Myers Squibb","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Orum Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Acquisition","leadProduct":"ORM-6151","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Bristol Myers Squibb","amount2":0.28000000000000003,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.28000000000000003,"dosageForm":"","sponsorNew":"Bristol Myers Squibb \/ Bristol Myers Squibb","highestDevelopmentStatusID":"6","companyTruncated":"Bristol Myers Squibb \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"BMS-986278","moa":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Avidity Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Collaboration","leadProduct":"RNA Therapeutic","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Discovery Platform","graph3":"Bristol Myers Squibb","amount2":2.2799999999999998,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":2.2799999999999998,"dosageForm":"","sponsorNew":"Bristol Myers Squibb \/ Bristol Myers Squibb","highestDevelopmentStatusID":"3","companyTruncated":"Bristol Myers Squibb \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Repotrectinib","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Karyopharm Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Collaboration","leadProduct":"Mezigdomide","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Bristol Myers Squibb \/ Karyopharm Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Bristol Myers Squibb \/ Karyopharm Therapeutics"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"SystImmune","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Collaboration","leadProduct":"BL-B01D1","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Bristol Myers Squibb","amount2":8.4000000000000004,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":8.4000000000000004,"dosageForm":"Infusion","sponsorNew":"Bristol Myers Squibb \/ Bristol Myers Squibb","highestDevelopmentStatusID":"6","companyTruncated":"Bristol Myers Squibb \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Agenus","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Licensing Agreement","leadProduct":"AGEN1777","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bristol Myers Squibb","amount2":1.5600000000000001,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":1.5600000000000001,"dosageForm":"Infusion","sponsorNew":"Bristol Myers Squibb \/ Bristol Myers Squibb","highestDevelopmentStatusID":"7","companyTruncated":"Bristol Myers Squibb \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"Ibrutinib","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Nivolumab","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Nivolumab","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Nivolumab","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"2Seventy Bio","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"Idecabtagene Vicleucel","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bristol Myers Squibb \/ 2seventy bio","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ 2seventy bio"},{"orgOrder":0,"company":"Turning Point Therapeutics","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Repotrectinib","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Turning Point Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Turning Point Therapeutics \/ Turning Point Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Turning Point Therapeutics \/ Turning Point Therapeutics"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"RayzeBio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Acquisition","leadProduct":"Actinium-225 Dotatate","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Bristol Myers Squibb","amount2":4.0999999999999996,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":4.0999999999999996,"dosageForm":"Infusion","sponsorNew":"Bristol Myers Squibb \/ Bristol Myers Squibb","highestDevelopmentStatusID":"10","companyTruncated":"Bristol Myers Squibb \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Karuna Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Acquisition","leadProduct":"Xanomeline","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Bristol Myers Squibb","amount2":14,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":14,"dosageForm":"Capsule","sponsorNew":"Bristol Myers Squibb \/ Bristol Myers Squibb","highestDevelopmentStatusID":"10","companyTruncated":"Bristol Myers Squibb \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Mirati Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Acquisition","leadProduct":"Adagrasib","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":5.7999999999999998,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":5.7999999999999998,"dosageForm":"Tablet, Film Coated","sponsorNew":"Bristol Myers Squibb \/ Bristol Myers Squibb","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"Idecabtagene Vicleucel","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Suspension for Infusion","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Nivolumab","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Exelixis","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Nivolumab","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bristol Myers Squibb \/ Exelixis","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Exelixis"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Ayala Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"AL102","moa":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bristol Myers Squibb \/ Bristol Myers Squibb","highestDevelopmentStatusID":"9","companyTruncated":"Bristol Myers Squibb \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Immunocore","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Collaboration","leadProduct":"IMC-F106C","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bristol Myers Squibb \/ Immunocore","highestDevelopmentStatusID":"10","companyTruncated":"Bristol Myers Squibb \/ Immunocore"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"VantAI","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Bristol Myers Squibb","amount2":0.67000000000000004,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0.67000000000000004,"dosageForm":"","sponsorNew":"Bristol Myers Squibb \/ Bristol Myers Squibb","highestDevelopmentStatusID":"3","companyTruncated":"Bristol Myers Squibb \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Celgene Corporation","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Enasidenib","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Celgene Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Celgene Corporation \/ AbbVie Inc","highestDevelopmentStatusID":"7","companyTruncated":"Celgene Corporation \/ AbbVie Inc"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Adagrasib","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Karuna Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Acquisition","leadProduct":"Xanomeline","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Bristol Myers Squibb","amount2":14,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":14,"dosageForm":"Capsule","sponsorNew":"Bristol Myers Squibb \/ Bristol Myers Squibb","highestDevelopmentStatusID":"10","companyTruncated":"Bristol Myers Squibb \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"Idecabtagene Vicleucel","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Suspension for Infusion","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"Idecabtagene Vicleucel","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Suspension for Infusion","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Nivolumab","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Adagrasib","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Ozanimod Hydrochloride","moa":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Accent Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Series C Financing","leadProduct":"ATX968","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Bristol Myers Squibb","amount2":0.080000000000000002,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0.080000000000000002,"dosageForm":"","sponsorNew":"Bristol Myers Squibb \/ Bristol Myers Squibb","highestDevelopmentStatusID":"5","companyTruncated":"Bristol Myers Squibb \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"RayzeBio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Acquisition","leadProduct":"Actinium-225 Dotatate","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bristol Myers Squibb \/ Bristol Myers Squibb","highestDevelopmentStatusID":"10","companyTruncated":"Bristol Myers Squibb \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"IFM Therapeutics","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Acquisition","leadProduct":"Undisclosed","moa":"","graph1":"Immunology","graph2":"Preclinical","graph3":"IFM Therapeutics","amount2":0.83999999999999997,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0.83999999999999997,"dosageForm":"","sponsorNew":"IFM Therapeutics \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"4","companyTruncated":"IFM Therapeutics \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"CytomX Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Collaboration","leadProduct":"BMS-986288","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bristol Myers Squibb","amount2":2,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":2,"dosageForm":"","sponsorNew":"Bristol Myers Squibb \/ Bristol Myers Squibb","highestDevelopmentStatusID":"7","companyTruncated":"Bristol Myers Squibb \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Nivolumab","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"Idecabtagene Vicleucel","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Nivolumab","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"Lisocabtagene Maraleucel","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Suspension for Infusion","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Nivolumab","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Repotrectinib","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Luspatercept","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Celgene Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Ozanimod Hydrochloride","moa":"","graph1":"Neurology","graph2":"Phase III","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bristol Myers Squibb \/ Bristol Myers Squibb","highestDevelopmentStatusID":"10","companyTruncated":"Bristol Myers Squibb \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Allyx Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"ALX-001","moa":"","graph1":"Neurology","graph2":"IND Enabling","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bristol Myers Squibb \/ Bristol Myers Squibb","highestDevelopmentStatusID":"5","companyTruncated":"Bristol Myers Squibb \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Nivolumab","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"Lisocabtagene Maraleucel","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Suspension for Infusion","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"2Seventy Bio","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"Idecabtagene Vicleucel","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bristol Myers Squibb \/ 2Seventy Bio","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ 2Seventy Bio"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Nivolumab","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Nivolumab","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Luspatercept","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Zai Lab","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Adagrasib","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Bristol Myers Squibb \/ Bristol Myers Squibb","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"2Seventy Bio","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"Idecabtagene Vicleucel","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bristol Myers Squibb \/ 2Seventy Bio","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ 2Seventy Bio"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Xanomeline","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Adagrasib","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Pathios Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Small molecule","year":"2024","type":"Series B Financing","leadProduct":"PTT-4256","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Bristol Myers Squibb","amount2":0.029999999999999999,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Bristol Myers Squibb \/ Bristol Myers Squibb","highestDevelopmentStatusID":"4","companyTruncated":"Bristol Myers Squibb \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Repertoire Immune Medicines","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Bristol Myers Squibb","amount2":1.8700000000000001,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":1.8700000000000001,"dosageForm":"","sponsorNew":"Bristol Myers Squibb \/ Bristol Myers Squibb","highestDevelopmentStatusID":"4","companyTruncated":"Bristol Myers Squibb \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Nivolumab","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Scenic Biotech","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Small molecule","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Genetic Disease","graph2":"Discovery Platform","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"Bristol Myers Squibb \/ Bristol Myers Squibb","highestDevelopmentStatusID":"3","companyTruncated":"Bristol Myers Squibb \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Editas Medicine","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Collaboration","leadProduct":"Alpha-beta T Cell Therapy","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Bristol Myers Squibb","amount2":3.8900000000000001,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":3.8900000000000001,"dosageForm":"","sponsorNew":"Bristol Myers Squibb \/ Bristol Myers Squibb","highestDevelopmentStatusID":"5","companyTruncated":"Bristol Myers Squibb \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Nivolumab","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Nivolumab","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Nivolumab","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Prothena","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"IRELAND","productType":"Large molecule","year":"2024","type":"Licensing Agreement","leadProduct":"PRX019","moa":"","graph1":"Neurology","graph2":"IND Enabling","graph3":"Bristol Myers Squibb","amount2":2.2000000000000002,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":2.2000000000000002,"dosageForm":"","sponsorNew":"Bristol Myers Squibb \/ Bristol Myers Squibb","highestDevelopmentStatusID":"5","companyTruncated":"Bristol Myers Squibb \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Menten AI","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Collaboration","leadProduct":"Peptide-based Therapy","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Bristol Myers Squibb \/ Bristol Myers Squibb","highestDevelopmentStatusID":"3","companyTruncated":"Bristol Myers Squibb \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Evotec","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"GERMANY","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Bristol Myers Squibb","amount2":4,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":4,"dosageForm":"","sponsorNew":"Bristol Myers Squibb \/ Bristol Myers Squibb","highestDevelopmentStatusID":"4","companyTruncated":"Bristol Myers Squibb \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"Lisocabtagene Maraleucel","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"Lisocabtagene Maraleucel","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Netherlands Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Nivolumab","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Bristol Myers Squibb \/ Netherlands Cancer Institute","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Netherlands Cancer Institute"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Nivolumab","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Nivolumab","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Nivolumab","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Repotrectinib","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"NeoPhore","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Small molecule","year":"2024","type":"Series B Financing","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Bristol Myers Squibb \/ Bristol Myers Squibb","highestDevelopmentStatusID":"4","companyTruncated":"Bristol Myers Squibb \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Eisai","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"JAPAN","productType":"Large molecule","year":"2024","type":"Termination","leadProduct":"Farletuzumab Ecteribulin","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":3.1000000000000001,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Bristol Myers Squibb \/ Bristol Myers Squibb","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Adagrasib","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Evotec","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"GERMANY","productType":"Small molecule","year":"2024","type":"Collaboration","leadProduct":"BMS-986419","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":4,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Bristol Myers Squibb \/ Bristol Myers Squibb","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Nivolumab","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Nivolumab","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Mavacamten","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Abata Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Financing","leadProduct":"ABA-101","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Bristol Myers Squibb \/ Bristol Myers Squibb","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Prime Medicine","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Collaboration","leadProduct":"T-Cell Therapy","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":3.6099999999999999,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Bristol Myers Squibb \/ Bristol Myers Squibb","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"2Seventy Bio","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"Fludarabine","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Bristol Myers Squibb \/ 2seventy Bio","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ 2seventy Bio"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Deucravacitinib","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Prime Medicine","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Collaboration","leadProduct":"T-Cell-based Therapy","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":3.6099999999999999,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Bristol Myers Squibb \/ Bristol Myers Squibb","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Nivolumab","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Ozanimod Hydrochloride","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Xanomeline","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Partnership","leadProduct":"ELP-004","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Bristol Myers Squibb \/ Bristol Myers Squibb","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Immatics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"IMA401","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Bristol Myers Squibb \/ Bristol Myers Squibb","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Nivolumab","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Bristol Myers Squibb

    Menu

    Bristol Myers Squibb

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    EXCIPIENTS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Bristol Myers Squibb

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Bristol Myers Squibb

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nivolumab,Ipilimumab

                            Therapeutic Area : Oncology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            BMS Gains CHMP Nod for Opdivo® + Yervoy® in MSI-High Colorectal Cancer

                            Details : Opdivo (nivolumab) in combination with Yervoy (ipilimumab) is being evaluated for the treatment of microsatellite instability–high or mismatch repair deficient metastatic colorectal cancer.

                            Brand Name : Opdivo

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            November 15, 2024

                            Lead Product(s) : Nivolumab,Ipilimumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Bristol Myers Squibb

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Bristol Myers Squibb

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : T-Cell-based Therapy

                            Therapeutic Area : Hematology

                            Study Phase : Preclinical

                            Recipient : Prime Medicine

                            Deal Size : $3,610.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            BMS Pays Prime $110M to Form T-cell Therapy Pact

                            Details : Prime Medicine will design optimized Prime Editor reagents for a select number of targets, including reagents that use its Prime Assisted Site-Specific Integrase Gene Editing (PASSIGE™) technology.

                            Brand Name : Undisclosed

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : $110.0 million

                            September 30, 2024

                            Lead Product(s) : T-Cell-based Therapy

                            Therapeutic Area : Hematology

                            Highest Development Status : Preclinical

                            Recipient : Prime Medicine

                            Deal Size : $3,610.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Bristol Myers Squibb

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Bristol Myers Squibb

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Idecabtagene Vicleucel,Lenalidomide,Fludarabine Phosphate

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : 2Seventy Bio

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Bristol Myers Squibb and 2seventy bio Update on KarMMa-9 Trial of Abecma in Myeloma

                            Details : Abecma (idecabtagene vicleucel) is a CAR T cell therapy which binds to BCMA on the surface of multiple myeloma cells. It is being evaluated for newly diagnosed multiple myeloma.

                            Brand Name : Abecma

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            September 25, 2024

                            Lead Product(s) : Idecabtagene Vicleucel,Lenalidomide,Fludarabine Phosphate

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : 2Seventy Bio

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Bristol Myers Squibb

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Bristol Myers Squibb

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Mavacamten

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            CAMZYOS® Phase 3 Data Confirms Efficacy in Obstructive Hypertrophic Cardiomyopathy

                            Details : Camzyos (mavacamten) is a cardiac myosin inhibitor, indicated for the treatment of adults with class II-III symptomatic obstructive hypertrophic cardiomyopathy.

                            Brand Name : Camzyos

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            September 01, 2024

                            Lead Product(s) : Mavacamten

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Bristol Myers Squibb

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Bristol Myers Squibb

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nivolumab,Ipilimumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Bristol Myers Squibb Receives EMA Validation for Opdivo and Yervoy in Liver Cancer

                            Details : Combination of Opdivo (nivolumab) and Yervoy(Ipilimumab) met the main goal of a late-stage study evaluating it as an initial treatment for patients with advanced hepatocellular carcinoma.

                            Brand Name : Opdivo

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            July 19, 2024

                            Lead Product(s) : Nivolumab,Ipilimumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Bristol Myers Squibb

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Bristol Myers Squibb

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Farletuzumab Ecteribulin

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Recipient : Eisai

                            Deal Size : $3,100.0 million

                            Deal Type : Termination

                            DEALS_DEV arrow-down

                            Japan's Eisai Terminates ADC Manufacturing Pact with BMS

                            Details : With the termination of its agreement with BMS, Eisai will solely focus on the development & commercialization of MORAb-202 (farletuzumab ecteribulin), is being evaluated for the treatment of NSCLC.

                            Brand Name : MORAb-202

                            Molecule Type : Large molecule

                            Upfront Cash : $650.0 million

                            July 01, 2024

                            Lead Product(s) : Farletuzumab Ecteribulin

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Recipient : Eisai

                            Deal Size : $3,100.0 million

                            Deal Type : Termination

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Bristol Myers Squibb

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Bristol Myers Squibb

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Adagrasib,Cetuximab

                            Therapeutic Area : Oncology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Bristol Myers Squibb Announces FDA Approval of KRAZATI with Cetuximab for CRC

                            Details : KRAZATI (adagrasib), a potent oral small-molecule inhibitor of KRASG12C, is indicated in combination with cetuximab for patients with locally advanced or metastatic colorectal cancer.

                            Brand Name : Krazati

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            June 21, 2024

                            Lead Product(s) : Adagrasib,Cetuximab

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Bristol Myers Squibb

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Bristol Myers Squibb

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nivolumab,Ipilimumab

                            Therapeutic Area : Oncology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            BMS: Opdivo + Yervoy Improve Survival in Advanced Hepatocellular Carcinoma

                            Details : Combination of Opdivo (nivolumab) and Yervoy(Ipilimumab) met the main goal of a late-stage study evaluating it as an initial treatment for patients with advanced hepatocellular carcinoma.

                            Brand Name : Opdivo

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            June 04, 2024

                            Lead Product(s) : Nivolumab,Ipilimumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Bristol Myers Squibb

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Bristol Myers Squibb

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nivolumab,Ipilimumab

                            Therapeutic Area : Oncology

                            Study Phase : Approved

                            Sponsor : Netherlands Cancer Institute

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Pre-Surgery Bristol Myers Combination Therapy Improves Skin Cancer Outcomes

                            Details : Opdivo (Nivolumab) and Yervoy (Ipilimumab) IV infusion, when given prior to surgery whose skin cancer had spread to lymph nodes, had better outcomes than those who did not get the drugs.

                            Brand Name : Opdivo

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            June 03, 2024

                            Lead Product(s) : Nivolumab,Ipilimumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Sponsor : Netherlands Cancer Institute

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Bristol Myers Squibb

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Bristol Myers Squibb

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nivolumab,Cisplatin,Gemcitabine

                            Therapeutic Area : Oncology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            BMS Receives EU Approval for Opdivo® with Cisplatin and Gemcitabine in Urothelial Cancer

                            Details : Opdivo (nivolumab) is a PD-1 immune checkpoint inhibitor, which is approved in combination with cisplatin and gemcitabine, for the patients with unresectable or metastatic urothelial carcinoma.

                            Brand Name : Opdivo

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            May 29, 2024

                            Lead Product(s) : Nivolumab,Cisplatin,Gemcitabine

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth